Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Hans Olsson, Agneta Jansson, Birgitta Holmlund & Cecilia Gunnarsson. (2013) Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue. Pathology and Laboratory Medicine International 5, pages 31-37.
Read now
Read now
Angelos K Koutras & T R Jeffry Evans. (2008) The epidermal growth factor receptor family in breast cancer. OncoTargets and Therapy 1, pages 5-19.
Read now
Read now
Birgitte Vrou Offersen, Jan Alsner, Karen Ege Olsen, Rikke Riisbro, Nils Brünner, Flemming Brandt Sørensen, Boe Sandahl Sørensen, Birgitte Olrik Schlemmer & Jens Overgaard. (2008) A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncologica 47:4, pages 618-632.
Read now
Read now
Andrea Nicolini, Paola Ferrari, Andrea Cavazzana, Angelo Carpi, Piero Berti & Paolo Miccoli. (2007) Conventional and New Emerging Prognostic Factors in Breast Cancer: An Update. Biomarkers in Medicine 1:4, pages 525-540.
Read now
Read now
Lena Larsson & Tord Berglundh. (2007) Accuracy of Assessment of Positive Cell Markers in Tissues Prepared With Immunohistochemistry and In Situ Hybridization Techniques. Journal of Histotechnology 30:3, pages 167-173.
Read now
Read now
Sofia Braga, Lissandra dal Lago, Chantal Bernard, Fátima Cardoso & Martine Piccart. (2006) Use of trastuzumab for the treatment of early stage breast cancer. Expert Review of Anticancer Therapy 6:8, pages 1153-1164.
Read now
Read now
Finn Edler von Eyben. (2006) Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. Critical Reviews in Clinical Laboratory Sciences 43:4, pages 291-323.
Read now
Read now
Articles from other publishers (20)
Min Li, Fangfei Yin, Lu Song, Xiuhai Mao, Fan Li, Chunhai Fan, Xiaolei Zuo & Qiang Xia. (2021) Nucleic Acid Tests for Clinical Translation. Chemical Reviews 121:17, pages 10469-10558.
Crossref
Crossref
Yiwei Tong, Xiaosong Chen, Xiaochun Fei, Lin Lin, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li & Kunwei Shen. (2018) Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. European Journal of Cancer 89, pages 9-18.
Crossref
Crossref
Carlynn Willmore-Payne, Kristy Damjanovich-Colmenares, Alexandra V. Pasi, Theresa L. Werner, H. Evin Gulbahce, Erinn Downs-Kelly & Katherine B. Geiersbach. (2016)
Inconsistent Results With Different Secondary Reflex Assays for Resolving
HER2
Status
. American Journal of Clinical Pathology 146:5, pages 618-626.
Crossref
Crossref
Vladimira Koudelakova, Jitka Berkovcova, Radek Trojanec, Jana Vrbkova, Lenka Radova, Jiri Ehrmann, Zdenek Kolar, Bohuslav Melichar & Marian Hajduch. (2015) Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. The Journal of Molecular Diagnostics 17:4, pages 446-455.
Crossref
Crossref
Troels Bechmann, Rikke Fredslund Andersen, Niels Pallisgaard, Jonna Skov Madsen, Else Maae, Erik Hugger Jakobsen, Anne Marie Bak Jylling, Karina Dahl Steffensen & Anders Jakobsen. (2013) Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. Journal of Cancer Research and Clinical Oncology 139:6, pages 995-1003.
Crossref
Crossref
Anna Larsson, Marie Fridberg, Alexander Gaber, Björn Nodin, Per Levéen, Göran Jönsson, Mathias Uhlén, Helgi Birgisson & Karin Jirström. (2012) Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer 12:1.
Crossref
Crossref
Keivan Majidzadeh-A, Rezvan Esmaeili & Nasrin Abdoli. (2011) TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer. BMC Research Notes 4:1.
Crossref
Crossref
D.L. Lildballe, K.Q.T. Nguyen, S.S. Poulsen, H.O. Nielsen & E. Nexo. (2011) Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 37:1, pages 72-79.
Crossref
Crossref
Isabell D. Witzel, Karin Milde-Langosch, Ralph M. Wirtz, Claudia Roth, Maike Ihnen, Sven Mahner, Christine Zu Eulenburg, Fritz Jänicke & Volkmar Müller. (2010) Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. Journal of Cancer Research and Clinical Oncology 136:11, pages 1709-1718.
Crossref
Crossref
Tommaso Susini, Cecilia Bussani, Giulia Marini, Jacopo Nori, Simone Olivieri, Cecilia Molino, Simonetta Bianchi, Vania Vezzosi, Milena Paglierani, Massimo Giachi, Elena Borrani & Gianfranco Scarselli. (2010) Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. Gynecologic Oncology 116:2, pages 234-239.
Crossref
Crossref
Fabíola E Rosa, Sara M Silveira, Cássia GT Silveira, Nádia A Bérgamo, Francisco A Moraes Neto, Maria AC Domingues, Fernando A Soares, José RF Caldeira & Silvia R Rogatto. (2009) Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer 9:1.
Crossref
Crossref
Gaston Demonty, Chantal Bernard-Marty, Fabio Puglisi, Isabelle Mancini & Martine Piccart. (2007) Progress and new standards of care in the management of HER-2 positive breast cancer. European Journal of Cancer 43:3, pages 497-509.
Crossref
Crossref
Marika Nestor, Tomas Ekberg, John Dring, Guus A.M.S. van Dongen, Kenneth Wester, Vladimir Tolmachev & Matti Anniko. (2007) Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose Radioimmunoassay. Tumor Biology 28:5, pages 253-263.
Crossref
Crossref
J. Jacquemier. 2007. Cancer du sein. Cancer du sein
415
424
.
Maria Ntoulia, Loukas Kaklamanis, Christos Valavanis, Maria Kafousi, Efstathios Stathopoulos, Petroula Arapantoni, Dimitris Mavroudis, Vassilis Georgoulias & Evi S. Lianidou. (2006) HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Clinical Biochemistry 39:9, pages 942-946.
Crossref
Crossref
Carmen M. Cabrera-Morales. (2006) PCR frente a FISH en la determinación del estado de Her2/neu en tumores de mama. Medicina Clínica 127:1, pages 35-36.
Crossref
Crossref
Pierre-Jean Lamy, Thibault Verjat, Malick Paye, Anne-Claire Servanton, Jean Grenier, Philippe Leissner & Bruno Mougin. (2006) NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. Clinical Chemistry and Laboratory Medicine (CCLM) 44:1.
Crossref
Crossref
P.-J. Lamy, I. Nanni, F. Fina, F. Bibeau, S. Romain, C. Dussert, F. Penault Llorca, J. Grenier, L'H. Ouafik & P.-M. Martin. (2018) Reliability and Discriminant Validity of HER2 Gene Quantification and Chromosome 17 Aneusomy Analysis by Real-Time PCR in Primary Breast Cancer. The International Journal of Biological Markers 21:1, pages 20-29.
Crossref
Crossref
John M S Bartlett. (2005) Pharmacodiagnostic Testing in Breast Cancer. American Journal of PharmacoGenomics 5:5, pages 303-315.
Crossref
Crossref
Bernhard Kaltenboeck & Chengming Wang. 2005.
219
259
.